{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:29:07Z","timestamp":1787498947879,"version":"build-2736575974"},"reference-count":146,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T00:00:00Z","timestamp":1676505600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Bullous pemphigoid (BP) is an autoimmune disease that mainly occurs in the elderly, severely affecting their health and life quality. Traditional therapy for BP is mainly based on the systemic use of corticosteroids, but long-term use of corticosteroids results in a series of side effects. Type 2 inflammation is an immune response largely mediated by group 2 innate lymphoid cells, type 2 T helper cells, eosinophils, and inflammatory cytokines, such as interleukin (IL)-4, IL-5 and IL-13. Among patients with BP, the levels of immunoglobulin E and eosinophils are significantly increased in the peripheral blood and skin lesions, suggesting that the pathogenesis is tightly related to type 2 inflammation. To date, various targeted drugs have been developed to treat type 2 inflammatory diseases. In this review, we summarize the general process of type 2 inflammation, its role in the pathogenesis of BP and potential therapeutic targets and medications related to type 2 inflammation. The content of this review may contribute to the development of more effective drugs with fewer side effects for the treatment of BP.<\/jats:p>","DOI":"10.3389\/fimmu.2023.1115083","type":"journal-article","created":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T07:40:43Z","timestamp":1676533243000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":24,"title":["Bullous pemphigoid: The role of type 2 inflammation in its pathogenesis and the prospect of targeted therapy"],"prefix":"10.3389","volume":"14","author":[{"given":"Luyao","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zihua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanting","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqun","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,2,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20743","article-title":"The global incidence of bullous pemphigoid: A systematic review and meta-analysis","volume":"186","author":"Persson","year":"2022","journal-title":"Br J Dermatol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2017.03.010","article-title":"Bullous pemphigoid","volume":"16","author":"Ba\u011fc\u0131","year":"2017","journal-title":"Autoimmun Rev"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.14503","article-title":"Mortality in bullous pemphigoid: A systematic review and meta-analysis of standardized mortality ratios","volume":"45","author":"Kridin","year":"2018","journal-title":"J Dermatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.841506","article-title":"Bullous pemphigoid associated with covid-19 vaccines: An Italian multicentre study","volume":"9","author":"Maronese","year":"2022","journal-title":"Front Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.jaad.2022.02.036","article-title":"Gliptin-associated bullous pemphigoid shows peculiar features of anti-Bp180 and -Bp230 humoral response: Results of a multicenter study","volume":"87","author":"Salemme","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.03.132","article-title":"Immune checkpoint inhibitor-related dermatologic adverse events","volume":"83","author":"Geisler","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s12016-007-0030-y","article-title":"The pathophysiology of bullous pemphigoid","volume":"33","author":"Kasperkiewicz","year":"2007","journal-title":"Clin Rev Allergy Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathol-012615-044313","article-title":"Mechanisms of disease: Pemphigus and bullous pemphigoid","volume":"11","author":"Hammers","year":"2016","journal-title":"Annu Rev Pathol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01506","article-title":"New insights into the pathogenesis of bullous pemphigoid: 2019 update","volume":"10","author":"Genovese","year":"2019","journal-title":"Front Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1590\/abd1806-4841.20199007","article-title":"Bullous pemphigoid","volume":"94","author":"Miyamoto","year":"2019","journal-title":"Anais brasileiros dermatol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(12)61140-4","article-title":"Pemphigoid diseases","volume":"381","author":"Schmidt","year":"2013","journal-title":"Lancet (London England)"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15405","article-title":"Increased frequency of multiple sclerosis among patients with bullous pemphigoid: A population-based cohort study on comorbidities anchored around the diagnosis of bullous pemphigoid","volume":"176","author":"Kibsgaard","year":"2017","journal-title":"Br J Dermatol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-020-02100-2","article-title":"Association of bullous pemphigoid and comorbid health conditions: A case-control study","volume":"313","author":"Lee","year":"2021","journal-title":"Arch Dermatol Res"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.11.018","article-title":"Diabetes mellitus and hyperglycemic complications in bullous pemphigoid","volume":"82","author":"Chai","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"adv00289","DOI":"10.2340\/00015555-3622","article-title":"Increased risk of squamous cell carcinoma of the skin and lymphoma among 5,739 patients with bullous pemphigoid: A Swedish nationwide cohort study","volume":"100","author":"Albadri","year":"2020","journal-title":"Acta dermato-venereol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1590\/abd1806-4841.20164935","article-title":"Quality of life, depression, anxiety and loneliness in patients with bullous pemphigoid. a case control study","volume":"91","author":"Kouris","year":"2016","journal-title":"Anais brasileiros dermatol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"adv00320","DOI":"10.2340\/00015555-3683","article-title":"Characteristics of pruritus in bullous pemphigoid and impact on quality of life: A prospective cohort study","volume":"100","author":"Briand","year":"2020","journal-title":"Acta dermato-venereol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2017.09.011","article-title":"Long-term systemic corticosteroid exposure: A systematic literature review","volume":"39","author":"Rice","year":"2017","journal-title":"Clin Ther"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13633","article-title":"First-line combination therapy with rituximab and corticosteroids provides a high complete remission rate in moderate-to-Severe bullous pemphigoid","volume":"173","author":"Cho","year":"2015","journal-title":"Br J Dermatol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18220","article-title":"Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European academy of dermatology and venereology (Eadv)","volume":"36","author":"Borradori","year":"2022","journal-title":"J Eur Acad Dermatol Venereol JEADV"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2014.11.001","article-title":"The 3 major types of innate and adaptive cell-mediated effector immunity","volume":"135","author":"Annunziato","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1126\/science.1221064","article-title":"New paradigms in type 2 immunity","volume":"337","author":"Pulendran","year":"2012","journal-title":"Sci (New York NY)"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/mi.2015.59","article-title":"Group 2 innate lymphoid cells utilize the Irf4-Il-9 module to coordinate epithelial cell maintenance of lung homeostasis","volume":"9","author":"Mohapatra","year":"2016","journal-title":"Mucosal Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/nature16161","article-title":"Tuft-Cell-Derived il-25 regulates an intestinal Ilc2-epithelial response circuit","volume":"529","author":"von Moltke","year":"2016","journal-title":"Nature"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1016\/j.jaci.2020.02.026","article-title":"Ilc2 activation by keratinocyte-derived il-25 drives il-13 production at sites of allergic skin inflammation","volume":"145","author":"Leyva-Castillo","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-63245-2_20","article-title":"Hypoxia and local inflammation in pulmonary artery structure and function","volume":"967","author":"Thompson","year":"2017","journal-title":"Adv Exp Med Biol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2016.04.049","article-title":"Programming of intestinal epithelial differentiation by il-33 derived from pericryptal fibroblasts in response to systemic infection","volume":"15","author":"Mahapatro","year":"2016","journal-title":"Cell Rep"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2014.09.006","article-title":"Innate lymphoid cells in inflammation and immunity","volume":"41","author":"McKenzie","year":"2014","journal-title":"Immunity"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201909-1722OC","article-title":"The role of the Tl1a\/Dr3 axis in the activation of group 2 innate lymphoid cells in subjects with eosinophilic asthma","volume":"202","author":"Machida","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/mi.2013.114","article-title":"The tnf-family cytokine Tl1a promotes allergic immunopathology through group 2 innate lymphoid cells","volume":"7","author":"Meylan","year":"2014","journal-title":"Mucosal Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.02.034","article-title":"Lipid regulation of group 2 innate lymphoid cell function: Moving beyond epithelial cytokines","volume":"141","author":"Doherty","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1111\/all.13974","article-title":"Evidence for the induction of Th2 inflammation by group 2 innate lymphoid cells in response to prostaglandin D(2) and cysteinyl leukotrienes in allergic rhinitis","volume":"74","author":"Tojima","year":"2019","journal-title":"Allergy"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/j.jaci.2019.06.011","article-title":"Thymic stromal lymphopoietin epigenetically upregulates fc receptor \u0393 subunit-related receptors on antigen-presenting cells and induces T(H)2\/T(H)17 polarization through dectin-2","volume":"144","author":"Liang","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.2332\/allergolint.13-OA-0672","article-title":"Il-33 promotes the induction and maintenance of Th2 immune responses by enhancing the function of Ox40 ligand","volume":"63","author":"Murakami-Satsutani","year":"2014","journal-title":"Allergol Int"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1300974","article-title":"Type 2 innate lymphoid cells drive Cd4+ Th2 cell responses","volume":"192","author":"Mirchandani","year":"2014","journal-title":"J Immunol (Baltimore Md 1950)"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2014.06.016","article-title":"Mhcii-mediated dialog between group 2 innate lymphoid cells and Cd4(+) T cells potentiates type 2 immunity and promotes parasitic helminth expulsion","volume":"41","author":"Oliphant","year":"2014","journal-title":"Immunity"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1111\/all.12446","article-title":"Group 2 innate lymphoid cells and Cd4+ T cells cooperate to mediate type 2 immune response in mice","volume":"69","author":"Drake","year":"2014","journal-title":"Allergy"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/9095275","article-title":"Eosinophils from physiology to disease: A comprehensive review","volume":"2018","author":"Ramirez","year":"2018","journal-title":"BioMed Res Int"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/b978-0-12-404717-4.00004-4","article-title":"The biology of thymic stromal lymphopoietin (Tslp)","volume":"66","author":"Ziegler","year":"2013","journal-title":"Adv Pharmacol (San Diego Calif)"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2015.11.028","article-title":"Il-33 drives eosinophil infiltration and pathogenic type 2 helper T-cell immune responses leading to chronic experimental ileitis","volume":"186","author":"De Salvo","year":"2016","journal-title":"Am J Pathol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1172\/jci108166","article-title":"Behavior of eosinophil leukocytes in acute inflammation. ii. eosinophil dynamics during acute inflammation","volume":"56","author":"Bass","year":"1975","journal-title":"J Clin Invest"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.160.3.1279","article-title":"Eosinophils bind rhinovirus and activate virus-specific T cells","volume":"160","author":"Handzel","year":"1998","journal-title":"J Immunol (Baltimore Md 1950)"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-015-8525-4","article-title":"The eosinophil in infection","volume":"50","author":"Ravin","year":"2016","journal-title":"Clin Rev Allergy Immunol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1007\/s11033-021-07067-5","article-title":"The role of indoleamine 2,3-dioxygenase in allergic disorders","volume":"49","author":"Esmaeili","year":"2022","journal-title":"Mol Biol Rep"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/icb.2009.115","article-title":"Eosinophils and Th2 immunity: Contemporary insights","volume":"88","author":"Spencer","year":"2010","journal-title":"Immunol Cell Biol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20070406","article-title":"Il-25 augments type 2 immune responses by enhancing the expansion and functions of tslp-Dc-Activated Th2 memory cells","volume":"204","author":"Wang","year":"2007","journal-title":"J Exp Med"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1111\/all.14318","article-title":"Type 2 immunity in the skin and lungs","volume":"75","author":"Akdis","year":"2020","journal-title":"Allergy"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2266","article-title":"Ige class switching and cellular memory","volume":"13","author":"Akdis","year":"2012","journal-title":"Nat Immunol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2009.11.017","article-title":"Ige, mast cells, basophils, and eosinophils","volume":"125","author":"Stone","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.603050","article-title":"Ige and igg antibodies as regulators of mast cell and basophil functions in food allergy","volume":"11","author":"Kanagaratham","year":"2020","journal-title":"Front Immunol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102661","article-title":"The role of T cells in pemphigus vulgaris and bullous pemphigoid","volume":"19","author":"Fang","year":"2020","journal-title":"Autoimmun Rev"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2007.9","article-title":"Correlation of ige autoantibody to Bp180 with a severe form of bullous pemphigoid","volume":"144","author":"Iwata","year":"2008","journal-title":"Arch Dermatol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2008.04.012","article-title":"Multicenter prospective study of the humoral autoimmune response in bullous pemphigoid","volume":"128","author":"Di Zenzo","year":"2008","journal-title":"Clin Immunol (Orlando Fla)"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-018-1817-9","article-title":"Bpdai and absis correlate with serum anti-Bp180 Nc16a igg but not with anti-Bp230 igg in patients with bullous pemphigoid","volume":"310","author":"Daneshpazhooh","year":"2018","journal-title":"Arch Dermatol Res"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.47102\/annals-acadmedsg.V44N4p119","article-title":"Anti-Bp180 Nc16a igg titres as an indicator of disease activity and outcome in Asian patients with bullous pemphigoid","volume":"44","author":"Cai","year":"2015","journal-title":"Ann Acad Med Singapore"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1586\/1744666x.2016.1123092","article-title":"Ige-mediated mechanisms in bullous pemphigoid and other autoimmune bullous diseases","volume":"12","author":"van Beek","year":"2016","journal-title":"Expert Rev Clin Immunol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2017.11.031","article-title":"Eosinophils mediate tissue injury in the autoimmune skin disease bullous pemphigoid","volume":"138","author":"Lin","year":"2018","journal-title":"J Invest Dermatol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2019.03.009","article-title":"Serum and blister fluid levels of cytokines and chemokines in pemphigus and bullous pemphigoid","volume":"18","author":"Kowalski","year":"2019","journal-title":"Autoimmun Rev"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.1998.02169.x","article-title":"Cytokine pattern in blister fluid and serum of patients with bullous pemphigoid: Relationships with disease intensity","volume":"138","author":"Ameglio","year":"1998","journal-title":"Br J Dermatol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1007\/s004030050272","article-title":"Il-5 levels in the serum and blister fluid of patients with bullous pemphigoid: Correlations with eosinophil cationic protein, rantes, ige and disease severity","volume":"290","author":"D'Auria","year":"1998","journal-title":"Arch Dermatol Res"},{"key":"B61","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1111\/cei.12566","article-title":"T Cell participation in autoreactivity to Nc16a epitopes in bullous pemphigoid","volume":"180","author":"Pickford","year":"2015","journal-title":"Clin Exp Immunol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.cyto.2014.09.011","article-title":"T Cell subsets and their signature cytokines in autoimmune and inflammatory diseases","volume":"74","author":"Raphael","year":"2015","journal-title":"Cytokine"},{"key":"B63","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/cea.13491","article-title":"Mechanisms of dupilumab","volume":"50","author":"Harb","year":"2020","journal-title":"Clin Exp Allergy"},{"key":"B64","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.jaad.2019.07.060","article-title":"Pathophysiologic mechanisms of itch in bullous pemphigoid","volume":"83","author":"Hashimoto","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1080\/08820139.2020.1832113","article-title":"Association between Th2 cytokine gene polymorphisms and risk of bullous pemphigoid","volume":"51","author":"Tabatabaei-Panah","year":"2022","journal-title":"Immunol investig"},{"key":"B66","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1016\/j.jaad.2017.12.022","article-title":"Dupilumab: A review of its use in the treatment of atopic dermatitis","volume":"78","author":"Gooderham","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.jaad.2020.01.089","article-title":"Dupilumab as a novel therapy for bullous pemphigoid: A multicenter case series","volume":"83","author":"Abdat","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.03.017","article-title":"Interleukin 4 and interleukin 13 inhibition: A promising therapeutic approach in bullous pemphigoid","volume":"83","author":"Geller","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2018.2526","article-title":"Dupilumab for the treatment of recalcitrant bullous pemphigoid","volume":"154","author":"Kaye","year":"2018","journal-title":"JAMA Dermatol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.611549","article-title":"Case report: Combination of omalizumab and dupilumab for recalcitrant bullous pemphigoid","volume":"11","author":"Seyed Jafari","year":"2020","journal-title":"Front Immunol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.16428","article-title":"Treatment of bullous pemphigoid with dupilumab: Dupilumab exerts its effect by primarily suppressing T-helper 2 cytokines","volume":"49","author":"Takamura","year":"2022","journal-title":"J Dermatol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.800609","article-title":"Commentary: Efficacy and safety of dupilumab in moderate-to-Severe bullous pemphigoid","volume":"12","author":"Wang","year":"2021","journal-title":"Front Immunol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15648","article-title":"Dupilumab combined with low-dose systemic steroid therapy improves efficacy and safety for bullous pemphigoid","volume":"35","author":"Yang","year":"2022","journal-title":"Dermatol Ther"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.738907","article-title":"Efficacy and safety of dupilumab in moderate-to-Severe bullous pemphigoid","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Immunol"},{"key":"B75","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1002\/art.41943","article-title":"Mepolizumab for eosinophilic granulomatosis with polyangiitis: A European multicenter observational study","volume":"74","author":"Bettiol","year":"2022","journal-title":"Arthritis Rheumatol (Hoboken NJ)"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-2600(21)00097-7","article-title":"Mepolizumab for chronic rhinosinusitis with nasal polyps (Synapse): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"9","author":"Han","year":"2021","journal-title":"Lancet Respir Med"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"New Engl J Med"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(12)60988-x","article-title":"Mepolizumab for severe eosinophilic asthma (Dream): A multicentre, double-blind, placebo-controlled trial","volume":"380","author":"Pavord","year":"2012","journal-title":"Lancet (London England)"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1702079","article-title":"Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis","volume":"376","author":"Wechsler","year":"2017","journal-title":"New Engl J Med"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1111\/all.13950","article-title":"Mepolizumab failed to affect bullous pemphigoid: A randomized, placebo-controlled, double-blind phase 2 pilot study","volume":"75","author":"Simon","year":"2020","journal-title":"Allergy"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-2600(15)00042-9","article-title":"Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: Results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials","volume":"3","author":"Castro","year":"2015","journal-title":"Lancet Respir Med"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0740-2","article-title":"Reslizumab in eosinophilic asthma: A review","volume":"77","author":"Deeks","year":"2017","journal-title":"Drugs"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-016-0583-2","article-title":"Reslizumab: First global approval","volume":"76","author":"Markham","year":"2016","journal-title":"Drugs"},{"key":"B84","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s13223-021-00619-1","article-title":"Successful induction treatment of bullous pemphigoid using reslizumab: A case report","volume":"17","author":"Rhyou","year":"2021","journal-title":"Allergy asthma Clin Immunol"},{"key":"B85","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.chest.2020.08.2083","article-title":"Real-world effectiveness of benralizumab in severe eosinophilic asthma","volume":"159","author":"Kavanagh","year":"2021","journal-title":"Chest"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1905248","article-title":"Benralizumab for the prevention of copd exacerbations","volume":"381","author":"Criner","year":"2019","journal-title":"New Engl J Med"},{"key":"B87","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1016\/j.jaip.2020.09.054","article-title":"Benralizumab as a steroid-sparing treatment option in eosinophilic granulomatosis with polyangiitis","volume":"9","author":"Guntur","year":"2021","journal-title":"J Allergy Clin Immunol In Pract"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19574","article-title":"Tralokinumab for moderate-to-Severe atopic dermatitis: Results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase iii trials (Ecztra 1 and ecztra 2)","volume":"184","author":"Wollenberg","year":"2021","journal-title":"Br J Dermatol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01583-1","article-title":"Tralokinumab: First approval","volume":"81","author":"Duggan","year":"2021","journal-title":"Drugs"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2016.1227319","article-title":"Lebrikizumab for the treatment of asthma","volume":"25","author":"Antoniu","year":"2016","journal-title":"Expert Opin investig Drugs"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2016.1182152","article-title":"Lebrikizumab in the treatment of asthma","volume":"16","author":"Bujarski","year":"2016","journal-title":"Expert Opin Biol Ther"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2020.0079","article-title":"Efficacy and safety of lebrikizumab, a high-affinity interleukin 13 inhibitor, in adults with moderate to severe atopic dermatitis: A phase 2b randomized clinical trial","volume":"156","author":"Guttman-Yassky","year":"2020","journal-title":"JAMA Dermatol"},{"key":"B93","doi-asserted-by":"publisher","first-page":"87","DOI":"10.2147\/jaa.S69932","article-title":"Profile of lebrikizumab and its potential in the treatment of asthma","volume":"8","author":"Maselli","year":"2015","journal-title":"J Asthma Allergy"},{"key":"B94","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.jaad.2018.01.017","article-title":"Efficacy and safety of lebrikizumab (an anti-Il-13 monoclonal antibody) in adults with moderate-to-Severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase ii trial (Treble)","volume":"78","author":"Simpson","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"B95","doi-asserted-by":"publisher","first-page":"adv00419","DOI":"10.2340\/00015555-3771","article-title":"Immunomodulator galectin-9 is increased in blood and skin of patients with bullous pemphigoid","volume":"101","author":"Pruessmann","year":"2021","journal-title":"Acta dermato-venereol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-2581","article-title":"Increased activity and apoptosis of eosinophils in blister fluids, skin and peripheral blood of patients with bullous pemphigoid","volume":"97","author":"Engmann","year":"2017","journal-title":"Acta dermato-venereol"},{"key":"B97","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1080\/07853890.2020.1742367","article-title":"Factors associated with the activity and severity of bullous pemphigoid: A review","volume":"52","author":"Liu","year":"2020","journal-title":"Ann Med"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16679","article-title":"Peripheral eosinophilia in bullous pemphigoid: Prevalence and influence on the clinical manifestation","volume":"179","author":"Kridin","year":"2018","journal-title":"Br J Dermatol"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.5021\/ad.2018.30.5.544","article-title":"Circulating eosinophil and neutrophil counts correlate with disease severity in bullous pemphigoid","volume":"30","author":"Park","year":"2018","journal-title":"Ann Dermatol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1111\/ajd.13547","article-title":"Tissue eosinophil levels as a marker of disease severity in bullous pemphigoid","volume":"62","author":"Gore Karaali","year":"2021","journal-title":"Australas J Dermatol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0107725","article-title":"Human eosinophils express the high affinity ige receptor, fc\u03f5ri, in bullous pemphigoid","volume":"9","author":"Messingham","year":"2014","journal-title":"PloS One"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1111\/exd.13782","article-title":"Mechanisms of pathogenic effects of eosinophil cationic protein and eosinophil-derived neurotoxin on human keratinocytes","volume":"27","author":"Amber","year":"2018","journal-title":"Exp Dermatol"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1186\/1465-9921-12-10","article-title":"Analysing the eosinophil cationic protein\u2013a clue to the function of the eosinophil granulocyte","volume":"12","author":"Bystrom","year":"2011","journal-title":"Respir Res"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2015.106","article-title":"Il-31 induces chemotaxis, calcium mobilization, release of reactive oxygen species, and Ccl26 in eosinophils, which are capable to release il-31","volume":"135","author":"Kunsleben","year":"2015","journal-title":"J Invest Dermatol"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-2951","article-title":"Eosinophils are a major source of interleukin-31 in bullous pemphigoid","volume":"98","author":"R\u00fcdrich","year":"2018","journal-title":"Acta dermato-venereol"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1172\/jci117196","article-title":"92-kd gelatinase is produced by eosinophils at the site of blister formation in bullous pemphigoid and cleaves the extracellular domain of recombinant 180-kd bullous pemphigoid autoantigen","volume":"93","author":"St\u00e5hle-B\u00e4ckdahl","year":"1994","journal-title":"J Clin Invest"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1111\/all.13131","article-title":"Evidence for a role of eosinophils in blister formation in bullous pemphigoid","volume":"72","author":"de Graauw","year":"2017","journal-title":"Allergy"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12464","article-title":"Eosinophil cationic protein levels parallel coagulation activation in the blister fluid of patients with bullous pemphigoid","volume":"29","author":"Tedeschi","year":"2015","journal-title":"J Eur Acad Dermatol Venereol JEADV"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2008.08880.x","article-title":"Activation of blood coagulation in bullous pemphigoid: Role of eosinophils, and local and systemic implications","volume":"160","author":"Marzano","year":"2009","journal-title":"Br J Dermatol"},{"key":"B110","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/j.1365-2249.2011.04391.x","article-title":"Activation of coagulation in bullous pemphigoid and other eosinophil-related inflammatory skin diseases","volume":"165","author":"Marzano","year":"2011","journal-title":"Clin Exp Immunol"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2021.5662","article-title":"Venous thromboembolism in chronic inflammatory skin diseases-the need to consider bullous pemphigoid","volume":"158","author":"Marzano","year":"2022","journal-title":"JAMA Dermatol"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.680871","article-title":"Risk factors for mucosal involvement in bullous pemphigoid and the possible mechanism: A review","volume":"8","author":"Chen","year":"2021","journal-title":"Front Med"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1111\/ddg.14494","article-title":"Immunological features and factors associated with mucocutaneous bullous pemphigoid - a retrospective cohort study","volume":"19","author":"St\u00e4nder","year":"2021","journal-title":"J der Deutschen Dermatologischen Gesellschaft"},{"key":"B114","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.coph.2018.12.007","article-title":"Pharmacological advances in pemphigoid","volume":"46","author":"Maglie","year":"2019","journal-title":"Curr Opin Pharmacol"},{"key":"B115","doi-asserted-by":"publisher","first-page":"3528","DOI":"10.3390\/jcm11123528","article-title":"Current and innovated managements for autoimmune bullous skin disorders: An overview","volume":"11","author":"Chu","year":"2022","journal-title":"J Clin Med"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01741-z","article-title":"Nemolizumab: First approval","volume":"82","author":"Keam","year":"2022","journal-title":"Drugs"},{"key":"B117","first-page":"193","article-title":"Immunopathology of bullous pemphigoid. basement membrane deposition of ige, alternate pathway components and fibrin","volume":"18","author":"Provost","year":"1974","journal-title":"Clin Exp Immunol"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2008.08858.x","article-title":"Ige autoantibodies against the intracellular domain of Bp180","volume":"160","author":"Dresow","year":"2009","journal-title":"Br J Dermatol"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15114","article-title":"Detection of ige autoantibodies to Bp180 and Bp230 and their relationship to clinical features in bullous pemphigoid","volume":"177","author":"Hashimoto","year":"2017","journal-title":"Br J Dermatol"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2012.02.003","article-title":"Ige recognition of bullous pemphigoid (Bp)180 and Bp230 in bp patients and elderly individuals with pruritic dermatoses","volume":"143","author":"Fania","year":"2012","journal-title":"Clin Immunol (Orlando Fla)"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18364","article-title":"Basement membrane zone ige deposition is associated with bullous pemphigoid disease severity and treatment results","volume":"182","author":"Kamata","year":"2020","journal-title":"Br J Dermatol"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-2101","article-title":"Enzyme-linked immunoassay index for anti-Nc16a igg and ige auto-antibodies correlates with severity and activity of bullous pemphigoid","volume":"96","author":"Kalowska","year":"2016","journal-title":"Acta dermato-venereol"},{"key":"B123","doi-asserted-by":"crossref","DOI":"10.2340\/0001555564243246","article-title":"Serum ige levels in patients with bullous pemphigoid and its correlation to the activity of the disease and anti-basement membrane zone antibodies","volume":"64","author":"Asbrink","year":"1984","journal-title":"Acta dermato-venereol"},{"key":"B124","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s00403-017-1789-1","article-title":"Ige autoantibodies and their association with the disease activity and phenotype in bullous pemphigoid: A systematic review","volume":"310","author":"Saniklidou","year":"2018","journal-title":"Arch Dermatol Res"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2007.08.008","article-title":"Serum levels of ige anti-Bp180 and anti-Bp230 autoantibodies in patients with bullous pemphigoid","volume":"49","author":"Ishiura","year":"2008","journal-title":"J Dermatol Sci"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.2340\/0001555577236","article-title":"Anti-230 kda circulating ige in bullous pemphigoid: Relationship with disease activity","volume":"77","author":"Cozzani","year":"1997","journal-title":"Acta dermato-venereol"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.15952","article-title":"Bp230 ige autoantibodies in topical-Steroid-Resistant bullous pemphigoid","volume":"48","author":"Shih","year":"2021","journal-title":"J Dermatol"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1089\/hyb.2011.0102","article-title":"Functional characterization of an ige-class monoclonal antibody specific for the bullous pemphigoid autoantigen, Bp180","volume":"31","author":"Messingham","year":"2012","journal-title":"Hybridoma (2005)"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2004.03.009","article-title":"Elevated expression of Cd23 on peripheral blood b lymphocytes from patients with bullous pemphigoid: Correlation with increased serum ige","volume":"35","author":"Inaoki","year":"2004","journal-title":"J Dermatol Sci"},{"key":"B130","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.jaci.2016.03.042","article-title":"Cd23 surface density on b cells is associated with ige levels and determines ige-facilitated allergen uptake, as well as activation of allergen-specific T cells","volume":"139","author":"Selb","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.5826\/dpc.1004a106","article-title":"Diminished expression of galectin-3 around blisters in bullous pemphigoid: An immunohistochemistry study","volume":"10","author":"Aghighi","year":"2020","journal-title":"Dermatol Pract conceptual"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215372","article-title":"Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria","volume":"368","author":"Maurer","year":"2013","journal-title":"New Engl J Med"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2004.00772.x","article-title":"Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (Gina 2002 step 4 treatment): Innovate","volume":"60","author":"Humbert","year":"2005","journal-title":"Allergy"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2004.11.053","article-title":"The anti-inflammatory effects of omalizumab confirm the central role of ige in allergic inflammation","volume":"115","author":"Holgate","year":"2005","journal-title":"J Allergy Clin Immunol"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01919","article-title":"Effects of omalizumab on fc\u03f5ri and ige expression in lesional skin of bullous pemphigoid","volume":"10","author":"Seyed Jafari","year":"2019","journal-title":"Front Immunol"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2018.12.015","article-title":"Ige blockade in autoimmunity: Omalizumab induced remission of bullous pemphigoid","volume":"198","author":"James","year":"2019","journal-title":"Clin Immunol (Orlando Fla)"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13758","article-title":"Successful treatment of bullous pemphigoid with omalizumab as corticosteroid-sparing agent: Report of two cases and review of literature","volume":"30","author":"Balakirski","year":"2016","journal-title":"J Eur Acad Dermatol Venereol JEADV"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.04.053","article-title":"Omalizumab therapy for bullous pemphigoid","volume":"71","author":"Yu","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1016\/j.annder.2020.08.053","article-title":"Refractory bullous pemphigoid with ige anti-Bp230 and igg anti-P200 antibodies successfully treated with omalizumab","volume":"148","author":"Sarrazin","year":"2021","journal-title":"Annales dermatol venereol"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1900408","article-title":"Ligelizumab for chronic spontaneous urticaria","volume":"381","author":"Maurer","year":"2019","journal-title":"New Engl J Med"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02331","article-title":"The intersection of ige autoantibodies and eosinophilia in the pathogenesis of bullous pemphigoid","volume":"10","author":"Messingham","year":"2019","journal-title":"Front Immunol"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.698522","article-title":"Thymic stromal lymphopoietin in cutaneous immune-mediated diseases","volume":"12","author":"Wang","year":"2021","journal-title":"Front Immunol"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/4594630","article-title":"Thymic stromal lymphopoietin is implicated in the pathogenesis of bullous pemphigoid by dendritic cells","volume":"2020","author":"Li","year":"2020","journal-title":"J Immunol Res"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1721805115","article-title":"Bp180 dysfunction triggers spontaneous skin inflammation in mice","volume":"115","author":"Zhang","year":"2018","journal-title":"Proc Natl Acad Sci United States America"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034975","article-title":"Tezepelumab in adults and adolescents with severe, uncontrolled asthma","volume":"384","author":"Menzies-Gow","year":"2021","journal-title":"New Engl J Med"},{"key":"B146","doi-asserted-by":"publisher","first-page":"4369","DOI":"10.3390\/ijms22094369","article-title":"Tezepelumab: A potential new biological therapy for severe refractory asthma","volume":"22","author":"Pelaia","year":"2021","journal-title":"Int J Mol Sci"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1115083\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T19:34:46Z","timestamp":1701891286000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1115083\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,16]]},"references-count":146,"alternative-id":["10.3389\/fimmu.2023.1115083"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1115083","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,16]]},"article-number":"1115083"}}